Shopping Cart
Remove All
Your shopping cart is currently empty
Anti-IFNAR1 Antibody
Copy Product Info
🥰Excellent
Synonyms:
Catalog No. T9901A-1269 Copy Product Info
🥰Excellent
Anti-IFNAR1 Antibody (Anifrolumab) is a humanized IgG1 kappa monoclonal antibody targeting the type I interferon receptor subunit 1 (IFNAR1). This product specifically binds to IFNAR1, blocking the interaction of all type I interferons (including all subtypes of IFN-alpha, IFN-beta, and IFN-omega) with the receptor complex. This inhibition blocks the activation of the downstream JAK/STAT signaling pathway, reduces the expression of interferon-stimulated genes (ISGs), and suppresses type I interferon-mediated immune responses.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $318 | Inquiry | Inquiry | |
| 5 mg | $958 | Inquiry | Inquiry | |
| 10 mg | $1,490 | Inquiry | Inquiry |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Antibody Information
Storage & Solubility Information
| Description | Anti-IFNAR1 Antibody (Anifrolumab) is a humanized IgG1 kappa monoclonal antibody targeting the type I interferon receptor subunit 1 (IFNAR1). This product specifically binds to IFNAR1, blocking the interaction of all type I interferons (including all subtypes of IFN-alpha, IFN-beta, and IFN-omega) with the receptor complex. This inhibition blocks the activation of the downstream JAK/STAT signaling pathway, reduces the expression of interferon-stimulated genes (ISGs), and suppresses type I interferon-mediated immune responses. |
| In vitro | Anti-IFNAR1 Antibody potently inhibits type I IFN signaling. In human PBMCs and various cell lines, it dose-dependently suppresses IFN-α-induced phosphorylation of STAT1, STAT3, and STAT5. It effectively blocks the expression of diverse interferon-stimulated genes (ISGs), thereby neutralizing the biological effects of elevated type I IFN levels [1]. |
| In vivo | In IFN-α-accelerated SLE mice or cynomolgus monkeys, systemic Anti-IFNAR1 Antibody leads to a significant and sustained reduction in interferon signatures (ISG expression) in blood and skin. This treatment modulates myeloid and lymphoid cell activation, slowing disease progression and reducing organ damage in autoimmune models [1]. |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | IFNAR1 |
| Isotype | IgG1 |
| Storage | Store at low temperature Store at -20°C Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: Anti-IFNAR1 Antibody chemical structure | Anti-IFNAR1 Antibody in vivo | Anti-IFNAR1 Antibody in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.